Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jaap Fransen

Showing results (81-90 of 108) with videos related to

Pageof 11
Sort By:
The Journal of Rheumatology|May 17, 2014
Determinants associated with work participation in patients with established rheumatoid arthritis taking tumor necrosis factor inhibitorsSofie H M Manders, Wietske Kievit, Annemarie L M A Braakman-Jansen, et al.
Trials|August 24, 2018
Hit hard and early: analysing the effects of high-dose methylprednisolone on nailfold capillary changes and biomarkers in very early systemic sclerosis: study protocol for a 12-week randomised controlled trialWieneke M T van den Hombergh, Brigit E Kersten, Hanneke K A Knaapen-Hans, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 12, 2015
Circulating Apoptotic Microparticles in Systemic Lupus Erythematosus Patients Drive the Activation of Dendritic Cell Subsets and Prime Neutrophils for NETosisJürgen Dieker, Jurjen Tel, Elmar Pieterse, et al.
Arthritis Research & Therapy|December 11, 2012
Meta-analysis identified the TNFA -308G > A promoter polymorphism as a risk factor for disease severity in patients with rheumatoid arthritisErik J M Toonen, Pilar Barrera, Jaap Fransen, et al.
Annals of the Rheumatic Diseases|August 14, 2013
Preliminary analysis of the very early diagnosis of systemic sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosisTünde Minier, Serena Guiducci, Silvia Bellando-Randone, et al.
Biomed Research International|October 9, 2014
Serum samples that have been stored long-term (>10 years) can be used as a suitable data source for developing cardiovascular risk prediction models in large observational rheumatoid arthritis cohortsElke E A Arts, Calin D Popa, Jacqueline P Smith, et al.
Rheumatology (Oxford, England)|November 1, 2017
The revised Bristol Rheumatoid Arthritis Fatigue measures and the Rheumatoid Arthritis Impact of Disease scale: validation in six countriesSarah Hewlett, John Kirwan, Christina Bode, et al.
The Journal of Rheumatology|September 3, 2009
The reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent does not influence the effect of a second TNF blocking agent in patients with rheumatoid arthritisMarlies Blom, Wietske Kievit, Jaap Fransen, et al.
BMC Musculoskeletal Disorders|December 17, 2013
Treating to the target of remission in early rheumatoid arthritis is cost-effective: results of the DREAM registryMarloes Vermeer, Wietske Kievit, Hillechiena H Kuper, et al.
Arthritis and Rheumatism|November 1, 2008
HMOX1 promoter polymorphism modulates the relationship between disease activity and joint damage in rheumatoid arthritisFrank A D T G Wagener, Erik J M Toonen, Lonneke Wigman, et al.
Pageof 11

Showing results (81-90 of 108) with videos related to

Sort By:
Pageof 11
The Journal of Rheumatology|May 17, 2014
Determinants associated with work participation in patients with established rheumatoid arthritis taking tumor necrosis factor inhibitorsSofie H M Manders, Wietske Kievit, Annemarie L M A Braakman-Jansen, et al.
Trials|August 24, 2018
Hit hard and early: analysing the effects of high-dose methylprednisolone on nailfold capillary changes and biomarkers in very early systemic sclerosis: study protocol for a 12-week randomised controlled trialWieneke M T van den Hombergh, Brigit E Kersten, Hanneke K A Knaapen-Hans, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 12, 2015
Circulating Apoptotic Microparticles in Systemic Lupus Erythematosus Patients Drive the Activation of Dendritic Cell Subsets and Prime Neutrophils for NETosisJürgen Dieker, Jurjen Tel, Elmar Pieterse, et al.
Arthritis Research & Therapy|December 11, 2012
Meta-analysis identified the TNFA -308G > A promoter polymorphism as a risk factor for disease severity in patients with rheumatoid arthritisErik J M Toonen, Pilar Barrera, Jaap Fransen, et al.
Annals of the Rheumatic Diseases|August 14, 2013
Preliminary analysis of the very early diagnosis of systemic sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosisTünde Minier, Serena Guiducci, Silvia Bellando-Randone, et al.
Biomed Research International|October 9, 2014
Serum samples that have been stored long-term (>10 years) can be used as a suitable data source for developing cardiovascular risk prediction models in large observational rheumatoid arthritis cohortsElke E A Arts, Calin D Popa, Jacqueline P Smith, et al.
Rheumatology (Oxford, England)|November 1, 2017
The revised Bristol Rheumatoid Arthritis Fatigue measures and the Rheumatoid Arthritis Impact of Disease scale: validation in six countriesSarah Hewlett, John Kirwan, Christina Bode, et al.
The Journal of Rheumatology|September 3, 2009
The reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent does not influence the effect of a second TNF blocking agent in patients with rheumatoid arthritisMarlies Blom, Wietske Kievit, Jaap Fransen, et al.
BMC Musculoskeletal Disorders|December 17, 2013
Treating to the target of remission in early rheumatoid arthritis is cost-effective: results of the DREAM registryMarloes Vermeer, Wietske Kievit, Hillechiena H Kuper, et al.
Arthritis and Rheumatism|November 1, 2008
HMOX1 promoter polymorphism modulates the relationship between disease activity and joint damage in rheumatoid arthritisFrank A D T G Wagener, Erik J M Toonen, Lonneke Wigman, et al.
Pageof 11